So another quarter has rolled around, and another blood test has been done. Here’s an analysis of my last 90 days of CGM data. This goes back to mid-December 2019 (so includes Christmas/NY). Compared with lab HbA1c Each day is different, but the above data is an average over the last 90 days. For the …
Dexcom’s G6 CGM looks like it’s finally coming to Australia. This article is an attempt to distill the answers to most of the common questions in one place. That is, the answers we know at this point. February 2020 The G6 system was introduced in the US in 2018. This week Australia’s TGA approved the …
Continuous Glucose Monitoring gives us lots of data, and various attempts have been made to distill it down into simple metrics. This is a difficult job as there can be a huge depth of data available in there, which can be lost if we only look at high level numbers. But people are used to …
What are “diabetes complications”? This is a term I have real problems with: it’s misleading, and has unfortunate impacts on everyone. I tend to think of there not actually being any such thing as a “diabetes complication”. There’s usually nothing “diabetic” about health complications. What are people referring to? Basically, at a crude level it’s about …
Recently I spent a day participating in a training course for endocrinology registrars (i.e. doctors). It was the Practical Skills Course for Endocrinology & General Medicine Advanced Trainees run by the Australian Diabetes Society. I’ve participated in this course for several years now. I was there as a consumer/demonstrator to help educate the attendees on things like …
News recently emerged about a safety recall of Medtronic insulin pumps in the US. News spread quickly across the internet, but an Australian perspective might be useful. It’s a recall through the US Food and Drug Adminstration, and thus does not apply to Australia. The pumps affected are the 630G and 670G pumps (manufactured during …